Thomas Weimbs publishes paper in the journal Cell Reports Medicine
Dr. Weimbs’ research confirms his earlier discoveries of the implications of ketogenic diet in polycystic kidney disease (PKD)
December 11, 2023
Dr. Weimb’s research team has succeeded in their first randomized controlled clinical trial of ketogenic metabolic therapy for PKD. Dr. Weimbs’ research has great implications for the treatment of PKD, previously known to be a genetic disease with no effective treatment preventing eventual kidney failure. Patients that had undergone ketogenic diets were found to have effectively paused the growth of the kidneys, which would have led to failure in normal PKD prognosis.
Thomas Weimbs is a CALS-affiliate from the Molecular, Cellular, and Developmental Biology Department.
Related Links
